{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-073909","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.878122+00:00","generated_at":"2026-05-17T20:34:13.432654+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ocular Therapeutix Q2 revenue falls 18% to $13.5M; net loss $67.8M; SOL-1 data Q1 2026","bullets":["Q2 net revenue $13.5M, down 18% YoY; DEXTENZA unit sales up 5% but net revenue pressured by reimbursement challenges.","Net loss $67.8M ($0.39/share) vs $43.8M ($0.26) YoY; R&D spend $51.1M (up 77%) driven by SOL trial costs.","Cash $391.1M; raised ~$97M via ATM in June; runway into 2028, well beyond SOL-1 and SOL-R data.","SOL-1 Phase 3 wet AMD top-line data on track for Q1 2026; SOL-R data expected 1H 2027 with streamlined rescue criteria.","Received FDA feedback on NPDR/DME program; Investor Day Sept 30 in NYC to detail strategy and commercial outlook."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-073909","json":"https://secwatch.observer/filing/0001104659-25-073909.json","markdown":"https://secwatch.observer/filing/0001104659-25-073909.md","text":"https://secwatch.observer/filing/0001104659-25-073909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/0001104659-25-073909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/tm2522503d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:34:13.432654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}